ES2176254T3 - Procedimiento para encapsular farmacos anti-informatorios no esteroideos. - Google Patents

Procedimiento para encapsular farmacos anti-informatorios no esteroideos.

Info

Publication number
ES2176254T3
ES2176254T3 ES94925799T ES94925799T ES2176254T3 ES 2176254 T3 ES2176254 T3 ES 2176254T3 ES 94925799 T ES94925799 T ES 94925799T ES 94925799 T ES94925799 T ES 94925799T ES 2176254 T3 ES2176254 T3 ES 2176254T3
Authority
ES
Spain
Prior art keywords
microencapsulation
microcapsules
procedure
biodisponibility
nsaid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94925799T
Other languages
English (en)
Inventor
Sambasiva Rao Ghanta
Robert Edmon Guisinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharma Solutions Inc
Original Assignee
Eurand America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand America Inc filed Critical Eurand America Inc
Application granted granted Critical
Publication of ES2176254T3 publication Critical patent/ES2176254T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA DESCRIPCION ESTA DIRIGIDA A LA PREPARACION DE MICROCAPSULAS DE ELEVADA CARGA NUCLEAR, ELEVADA BIODISPONIBILIDAD, DE SABOR ENMASCARADO E INDIVIDUALES, MEDIANTE LA MICROENCAPSULACION DE MATERIALES FARMACOLOGICOS DE NSAID INSOLUBLES EN AGUA CON LA AUSENCIA SUSTANCIAL DE AGLOMERADOS DE MICROCAPSULAS. ESTAS MICROCAPSULAS DE SABOR ENMASCARADO CONTIENEN UNA ELEVADA CARGA NUCLEAR, POR EJEMPLO APROXIMADAMENTE 83+ % EN PESO DE DICHO MATERIAL FARMACOLOGICO DE NSAID QUE POSEE UNA ELEVADA BIODISPONIBILIDAD Y QUE ENTONCES PUEDE FORMULARSE EN COMPRIMIDOS MASTICABLES Y SUSPENSIONES ACUOSAS LIQUIDAS PARA UN USO MEDICINAL. EL ACETATO FTALATO DE CELULOSA Y LA GELATINA SON EL MATERIAL DE PARED POLIMERICO PARA LA MICROENCAPSULACION. SON PARAMETROS DEL PROCEDIMIENTO IMPORTANTES EL CONTROL DEL PH, LA ADICION CONTROLADA DE UNA SAL DE HOFMEISTER (LIOTROPICA), LA MICROENCAPSULACION DEL MEDICAMENTE NSAID INSOLUBLE EN AGUA CON UNA FASE LIQUIDA DE UN MATERIAL PARA LA MICROENCAPSULACION DE ACETATO FTALATO DE CELULOSA Y GELATINA, Y LA POSTERIOR INSOLUBILIZACION DE DICHO MATERIAL PARA LA ENCAPSULACION LIQUIDO DESPUES DE QUE CUBRA EL NUCLEO DE MEDICAMENTO CON ACIDO DILUIDO, PARA LOGRAR LA MICROCAPSULAS INDIVIDUALES APROPIADAS PARA OBTENER UNOS MATERIALES FARMACOLOGICOS DE NSAID INSOLUBLES EN AGUA, DE SABOR ENMASCARADO, DE ELEVADA BIODISPONIBILIDAD, EN ESPECIAL NAPROXENO E IBUPROFENO, SOLO MEDIANTE ENCAPSULACION.
ES94925799T 1993-08-13 1994-08-09 Procedimiento para encapsular farmacos anti-informatorios no esteroideos. Expired - Lifetime ES2176254T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10602493A 1993-08-13 1993-08-13

Publications (1)

Publication Number Publication Date
ES2176254T3 true ES2176254T3 (es) 2002-12-01

Family

ID=22309067

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94925799T Expired - Lifetime ES2176254T3 (es) 1993-08-13 1994-08-09 Procedimiento para encapsular farmacos anti-informatorios no esteroideos.

Country Status (14)

Country Link
US (2) US5653993A (es)
EP (1) EP0818992B1 (es)
AT (1) ATE216578T1 (es)
AU (1) AU7559594A (es)
BR (1) BR9407246A (es)
CA (1) CA2169376C (es)
DE (1) DE69430491T2 (es)
DK (1) DK0818992T3 (es)
ES (1) ES2176254T3 (es)
IL (1) IL110621A (es)
MY (1) MY111453A (es)
PT (1) PT818992E (es)
WO (1) WO1995005166A1 (es)
ZA (1) ZA945944B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN969796A0 (en) 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
AU719137B2 (en) * 1996-05-07 2000-05-04 Mayne Pharma International Pty Ltd Taste masked liquid suspensions
FR2753093B1 (fr) * 1996-09-06 1998-10-16 Oreal Composition de teinture d'oxydation pour fibres keratiniques comprenant un polymere amphiphile anionique
JP2001505188A (ja) * 1996-09-26 2001-04-17 オゥクラホゥマ、メディカル、リサーチ、ファウンデイシャン Ｎ―Ｌ―α―アスパルチル―Ｌ―フェニルアラニン１―メチルエステル及びその誘導体の疾患後退への使用
GB9625589D0 (en) 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
FR2785539B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
BR0009557A (pt) 1999-04-06 2002-05-28 Ethypharm Lab Prod Ethiques Suspensão farmacêutica para beber de ibuprofeno
CN1288730A (zh) * 1999-09-07 2001-03-28 麦克内尔-Ppc股份有限公司 轻泻组合物
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
EP1411899B1 (en) * 2001-08-01 2009-03-11 Novartis AG Taste masking composition
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) * 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
WO2003077842A2 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company Palatable oral suspension and method
AU2003220551A1 (en) * 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
ITMI20032523A1 (it) * 2003-12-19 2005-06-20 Acraf Forma di dosaggio per uso orale comprendente un farmaco
KR100694235B1 (ko) * 2005-04-21 2007-03-14 영남대학교 산학협력단 새로운 이부프로펜 함유 젤라틴 초미세 미립구
CN101563074B (zh) * 2006-10-20 2012-11-07 麦克内尔-Ppc股份有限公司 乙酰氨基酚/布洛芬组合
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
KR101560176B1 (ko) * 2007-10-31 2015-10-14 맥네일-피피씨, 인코포레이티드 구강내 붕해성 투여 형태
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
CN103619514B (zh) * 2010-09-20 2016-09-28 Spi制药公司 微包囊方法和制品
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
HK1212889A1 (zh) 2012-09-18 2016-06-24 Mcneil-Ppc, Inc. 包含低熔点丙酸衍生物颗粒的缓释口服剂型
CA2884119A1 (en) 2012-09-18 2014-03-27 Mcneil-Ppc, Inc. Low melting propionic acid derivative particles for use in oral dosage forms
WO2014165272A1 (en) 2013-03-12 2014-10-09 Panacea Biomatx, Inc. Method and system for making customized formulations for individuals
US9789066B2 (en) 2014-01-10 2017-10-17 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
JP7653218B2 (ja) 2016-05-05 2025-03-28 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1148784B (it) * 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
JPS5858146A (ja) * 1981-10-05 1983-04-06 Tanabe Seiyaku Co Ltd 速放性マイクロカプセル
JPS59193816A (ja) * 1983-04-19 1984-11-02 Morishita Jintan Kk 腸溶性軟カプセルの製造法
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1214629B (it) * 1985-08-29 1990-01-18 Formenti Farmaceutici Spa Procedimento di microincapsulazione di un medicamento,medicamento cosi'preparato,e composizioni farmaceutiche che lo comprendono
IN166447B (es) * 1985-11-27 1990-05-12 Ethicon Inc
US4835186A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
US4835187A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
US4835188A (en) * 1987-12-08 1989-05-30 American Home Products Corporation Spray dried ibuprofen
NZ234587A (en) * 1989-08-04 1991-11-26 Mcneil Ppc Inc A chewable pharmaceutical tablet of compressed coated granules
IE902829A1 (en) * 1989-08-14 1991-02-27 Eurand America Microencapsulated taste-masked water-insoluble nsaid drug¹materials

Also Published As

Publication number Publication date
IL110621A0 (en) 1994-11-11
IL110621A (en) 1999-10-28
BR9407246A (pt) 1996-09-24
DE69430491D1 (de) 2002-05-29
PT818992E (pt) 2002-08-30
DK0818992T3 (da) 2002-08-19
US5814332A (en) 1998-09-29
US5653993A (en) 1997-08-05
CA2169376C (en) 2003-10-21
ATE216578T1 (de) 2002-05-15
WO1995005166A1 (en) 1995-02-23
DE69430491T2 (de) 2002-08-08
AU7559594A (en) 1995-03-14
MY111453A (en) 2000-05-31
EP0818992B1 (en) 2002-04-24
EP0818992A1 (en) 1998-01-21
CA2169376A1 (en) 1995-02-23
ZA945944B (en) 1996-02-08

Similar Documents

Publication Publication Date Title
Fliesler et al. Chemistry and metabolism of lipids in the vertebrate retina
Douglas et al. The influence of calcium on the secretory response of the submaxillary gland to acetylcholine or to noradrenaline
FI69564C (fi) Doseringsenhet foer kontrollerad frigoering av ett terapeutiskt aktivt medel
GB2297907A (en) Liposomes containing particulate materials
MX25768A (es) Comprimido en forma de capsula y metodo para su produccion.
GB1286412A (en) Improved inflatable prosthesis
ES2188612T3 (es) Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
NO904754L (no) Kapsel for innkapsling av biologisk aktive materialer, fremgangsmaate for fremstilling av denne, samt anvendelse derav.
ES2056832T3 (es) Un vehiculo de liberacion para un ingrediente activo.
MY111453A (en) Procedure for encapsulating ibuprofen
GEP20022734B (en) Pharmaceutical Preparation Comprising Lyophilized Liposomes Encapsulating an Active Principle Which Is Highly Insoluble in Water, and the Process for Preparing the Said Preparation
EP0338383A3 (en) Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
DeFuria et al. Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report
NZ226001A (en) Hair restorer and stimulant containing trigonelline and vitamin
WO1998027966A3 (en) Encapsulated cells producing antibodies
Fischer et al. Severe contact dermatitis due to nitroglycerin patches
Gilfoil et al. 5-Hydroxytryptamine bradykinin and histamine as mediators of inflammatory hyperesthesia
Du et al. Autoradiographic approach to the developmental study on the binding sites of AVP4-8 in rat hippocampus
Taraskevich et al. Stimulant effect of 5-hydroxytryptamine on action potential activity in pars intermedia cells of the lizard Anolis carolinensis: contrasting effects in pars intermedia of rat and rostral pars distalis of fish (Alosa pseudoharengus)
JPS55141405A (en) Production of microcapsule containing placental extract for cosmetics and cosmetic containing the same
JPS579711A (en) Preparation of prolonged release type complex
Akatsu et al. Comparative effects of non-steroidal anti-inflammatory drugs, mefenamic acid, metiazinic acid and glucametacin on the inflammatory response induced by subcutaneous implantation of human dental plaque and on the mitotic activity of isoproterenol-stimulated parotid glands of rats
Skorokhodova et al. Morphofunctional status of blood and bone marrow cells in acute experimental hepatitis induced by allyl alcohol
Shabanov et al. Effect of intracisternal administration of antisera against neurospecific enolase (protein 14-3-2) on avoidance behavior in rats
Sokol'nikov et al. Calcium metabolism in the case of vitamin D and K deficiencies